Showing results (41-50 of 242) with videos related to

Sort By:
Pageof 25
Patient Related Outcome Measures|November 23, 2018
The importance of patient-reported outcomes in clinical trials and strategies for future optimizationRebecca Mercieca-Bebber, Madeleine T King, Melanie J Calvert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 28, 2015
An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility StudyDavid Mizrahi, Carolyn Broderick, Michael Friedlander, et al.
The Oncologist|August 13, 2011
If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancerKate Webber, Kelly Mok, Barbara Bennett, et al.
Breast Cancer Research : BCR|December 19, 2008
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agendaBettina Meiser, Kathy Tucker, Michael Friedlander, et al.
Nature Reviews. Clinical Oncology|November 10, 2010
The role of BRCA mutation testing in determining breast cancer therapyAlison H Trainer, Craig R Lewis, Kathy Tucker, et al.
JAMA Oncology|February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysisGeorgia Ritchie, Harry Gasper, Johnathan Man, et al.
Gynecologic Oncology|April 22, 2004
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancerDanny Rischin, Kelly-Anne Phillips, Michael Friedlander, et al.
JCO Precision Oncology|July 23, 2021
Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-AnalysisPeey-Sei Kok, Won-Hee Yoon, Sally Lord, et al.
Gynecologic Oncology|January 16, 2014
Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needsPhyllis N Butow, Melanie A Price, Melanie L Bell, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation frameworkDoah Cho, Sarah J Lord, John Simes, et al.
Pageof 25